Elasmogen is a biopharmaceutical company that specializes in the development of innovative therapeutics using its proprietary soloMER® technology. This platform focuses on creating fully humanized, single-chain therapeutics derived from variable new-antigen receptors (VNARs), which are naturally occurring binding domains found in sharks. These VNARs are significantly smaller than traditional antibodies, making them highly advantageous for therapeutic applications, particularly in targeting autoimmune diseases, cancer, and facilitating intracellular delivery. The unique architecture of soloMERs allows for rapid reformatting, enabling the generation of multifunctional therapeutic products with differentiated binding interactions and novel mechanisms of action.

In addition to soloMERs, Elasmogen is actively engaged in collaborations to enhance its therapeutic offerings. For instance, the company has partnered with Almac Discovery to develop next-generation oncology medicines based on VNAR technology. This collaboration aims to optimize the binding and selectivity of VNAR formats, potentially leading to first-in-class targeted therapeutics. Elasmogen's commitment to strong scientific principles and patient benefit is reflected in its robust intellectual property portfolio, which includes over 20 patents across various territories, positioning the company as a leader in the biopharmaceutical landscape.

United Kingdom

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases.
Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Elasmogen

Company Details